Comparing 7 vs 14 days of antifungal treatment for candidemia
Part of Infections clinical trials.
This study compares a shorter treatment (7 days) with the standard 14-day treatment for uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you qualify, you may receive the shorter treatment, which could be just as effective with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have candidemia (Candida in blood) but no other deep Candida infection.
- You have not received more than 5 days of antifungal treatment already.
- You do not have a weakened immune system from HIV, organ transplant, cancer treatment, or low white blood cell counts.
- Your doctors can remove any infected catheters or devices if present.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of the antifungal caspofungin (7 days total) is as effective as the usual longer treatment for people with uncomplicated candidemia, a yeast infection in the blood. Participating patients must already be on caspofungin and have shown clear blood cultures for 7 days.
This study tests whether a shorter course of antifungal medication works as well as the standard longer course for patients with a yeast infection in the blood (candidemia) that is not complicated by spread to other organs. If you have cleared the infection from your blood and are fever-free, you may be able to stop treatment sooner.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This trial studies two types of antifungal medicines (amphotericin B and azoles) to see which works better for people with invasive fungal disease. It aims to help doctors choose the safest and most effective treatment.
This study looks at how Candida infections form biofilms (protective coatings) and resist antifungal treatments. It may help find better ways to treat serious Candida infections in people with weakened immune systems or after medical procedures.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.